TY - JOUR
T1 - Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion
AU - Coscas, Gabriel
AU - Augustin, Albert
AU - Bandello, Francesco
AU - De Smet, Marc D.
AU - Lanzetta, Paolo
AU - Staurenghi, Giovanni
AU - Parravano, Maria Cristina
AU - Udaondo, Patricia
AU - Moisseiev, Elad
AU - Soubrane, Gisele
AU - Yatziv, Yossi
AU - Loewenstein, Anat
PY - 2013/10/14
Y1 - 2013/10/14
N2 - Purpose: To review the current practice of retreatment with Ozurdex injections in patients with macu-lar edema (ME) secondary to retinal vein occlusion (RVO), and to recommend simple guidelines for Ozurdex reinjection in management of RVO. Methods: This was a multicenter retrospective study of patients who received more than 2 Ozurdex injections for the treatment of ME in RVO. Recorded parameters included percent of patients with a 15-letter gain, visual acuity (VA) improvement from baseline, change in central macular thickness (CMT), time to reinjection, and occurrence of any complications. Results: A total of 128 patients were included, 58 (45.3%) with central RVO (CRVO) and 70 (54.7%) with branch RVO (BRVO). Mean interval for Ozurdex reinjection was 5.9 months following the first injection and 8.7 months following the second. A >15-letter gain in VA was observed in 34 (48.8%) patients with CRVO and 16 (28%) patients with BRVO. Mean overall VA improvement at month 6 did not show significance (p>0.05); however, a significantly better mean VA improvement was seen in treatment-naïve eyes (p
AB - Purpose: To review the current practice of retreatment with Ozurdex injections in patients with macu-lar edema (ME) secondary to retinal vein occlusion (RVO), and to recommend simple guidelines for Ozurdex reinjection in management of RVO. Methods: This was a multicenter retrospective study of patients who received more than 2 Ozurdex injections for the treatment of ME in RVO. Recorded parameters included percent of patients with a 15-letter gain, visual acuity (VA) improvement from baseline, change in central macular thickness (CMT), time to reinjection, and occurrence of any complications. Results: A total of 128 patients were included, 58 (45.3%) with central RVO (CRVO) and 70 (54.7%) with branch RVO (BRVO). Mean interval for Ozurdex reinjection was 5.9 months following the first injection and 8.7 months following the second. A >15-letter gain in VA was observed in 34 (48.8%) patients with CRVO and 16 (28%) patients with BRVO. Mean overall VA improvement at month 6 did not show significance (p>0.05); however, a significantly better mean VA improvement was seen in treatment-naïve eyes (p
KW - Dexamethasone implant
KW - Macular edema
KW - Ozurdex
KW - Retinal vein occlusion
KW - Retreatment
UR - http://www.scopus.com/inward/record.url?scp=84889632758&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84889632758&partnerID=8YFLogxK
U2 - 10.5301/ejo.5000376
DO - 10.5301/ejo.5000376
M3 - Article
C2 - 24249150
AN - SCOPUS:84889632758
VL - 24
SP - 1
EP - 9
JO - European Journal of Ophthalmology
JF - European Journal of Ophthalmology
SN - 1120-6721
IS - 1
ER -